Search Medical Condition
Please enter condition
Please choose location from dropdown

Maple Grove, Minnesota Clinical Trials

A listing of Maple Grove, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (166) clinical trials

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

Nutritional epigenetics denotes gene-diet interactions and highlights the modulatory role of nutrition in aging and age-related diseases such as cancer, CVD (cardiovascular disease), diabetes and neurodegenerative disorders. Nutrients are a source of epigenetic modification; they are able to regulate the placement of histone modifiers distinguishing phenotype from genotype. The energy ...

Phase N/A

0.0 miles

Learn More »

An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

This is a multicenter, double- blind extension study of Oral Budesonide Suspension (OBS) in adults and adolescents (11 to 55 years of age, inclusive) with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-301 induction study (NCT02605837). The primary objective is to evaluate the maintenance of efficacy of OBS ...

Phase

2.04 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.

Phase

2.7 miles

Learn More »

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

This will be a prospective, open-label, single-arm, historically controlled, multicenter phase 3 study measuring the safety, efficacy and pharmacokinetics and tolerability of GC5107 in subjects with Primary Humoral Immunodeficiency disease (PHID). Subjects will receive intravenous infusions of the investigational product at the same dose and interval as used for their ...

Phase

2.7 miles

Learn More »

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

This is a prospective, multi-center, open-label, single-sequence, 6-month, pharmacokinetic, safety and tolerability study of IGSC 20% in subjects with primary immunodeficiency. Approximately 50 subjects will be enrolled in order to have approximately 30 adult subjects and 12 to 15 pediatric subjects (age 2-16 years) completing treatment with subcutaneously administered IGSC ...

Phase

2.7 miles

Learn More »

A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.

Phase

2.7 miles

Learn More »

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.

Phase

2.7 miles

Learn More »

Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease

This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability ...

Phase N/A

2.7 miles

Learn More »

Triple Combination Therapy in High Risk Crohn's Disease

The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who have Crohn's Disease. This study will look at the endoscopic remission and mucosal healing of gastrointestinal tract of people who take vedolizumab as triple combination therapy with adalimumab and methotrexate. The study ...

Phase

2.7 miles

Learn More »

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

This program consists of 3 separate studies: a 48-week Phase 2 dose-ranging study (GALAXI 1) and two 48-week Phase 3 confirmatory studies (GALAXI 2 and GALAXI 3). In Phase 2, safety and efficacy of guselkumab dose regimens will be evaluated to support the selection of induction and maintenance dose regimens ...

Phase

2.7 miles

Learn More »